Programme

DRAFT PROGRAMME

Day 1

14:00 – 14:15   Welcome

14:15 – 14:50   Keynote lecture: Microbiome and Anticancer 

14:50 – 15:10   Impact of the microbiome during childhood (including 5-minute discussion)

15:10 – 15:30   Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation (including 5-minute discussion)

15:30 – 15:50   Longitudinal study of murine microbiota activity and interactions with the host during acute inflammation and recovery (including 5-minute discussion)

15:50 – 16.30   COFFEE BREAK

16:30 – 16:50   Potential of fecal microbiota for early-stage detection of colorectal cancer (including 5-minute discussion)

16:50 – 17:10   Crosstalk of the microbiome and NK T-cells (including 5-minute discussion)

17:10- 17:30   Dietary factors – regulators of the gut microbiome (including 5-minute discussion)

17:30 – 17:50   Rethinking the bile acid/gut microbiome axis in cancer (including 5-minute discussion)

17:50 – 18:10   Gut microbiota-derived propionate reduces cancer cell proliferation in the liver (including 5-minute discussion)

END OF DAY 1

19:30   Networking Event in Munich

Day 2

09:30 – 10:05   Keynote lecture: The role of the Microbiome on Anticancer Therapy

10:05 – 10:25   Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment (including 5-minute discussion)

10:25 – 10:45   Interplay of innate lymphoid cells and the microbiota (including 5-minute discussion)

10:45 – 11.15   COFFEE BREAK

11:15 – 11:35   The Intestinal Microbiota Modulates the Anticancer – Immune Effects of Cyclophosphamide (including 5-minute discussion)

11:35 – 11:55   Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity (including 5-minute discussion)

CLOSING REMARKS

12:00 – 12:30   Concluding remarks and discussion

12:30   END OF THE MEETING